Impact of toll-like receptor 4 variations on nasopharyngeal carcinoma risk and survival in tunisian population
DOI:
https://doi.org/10.62438/tunismed.v102i2.4270Keywords:
Nasopharyngeal carcinoma, TLR4, gene, polymorphism, riskAbstract
Introduction: The Toll-like receptor 4 (TLR4), an important member of the host's innate immune response, is coded by a polymorphic gene. This polymorphism could be a predisposing factor for NasoPharyngeal Carcinoma (NPC).
Aim: To determine the association between TLR4 gene polymorphisms and the susceptibility to NPC in a cohort of Tunisian affected patients.
Methods: Genomic DNAs from 245 unrelated patients affected by undifferentiated carcinoma type (UCNT) and 264 unrelated healthy controls were genotyped for the five single nucleotides polymorphisms (SNPs) of TLR4 locus (4434 A>G (rs1927914),7263 G>C (rs10759932), 6134 A>G(rs4986790), 8851C>T (rs 4986791), 5272 T>C(rs11536889), +8469 T>C (rs11536891)) by Taqman® 5’-nuclease assay.
Results: Among all polymorphisms studied, only the rs4986790 G and rs4986791 T alleles were significantly more prevalent in patients’ group than controls (45% vs. 38%; p=0.03; pc=0.06) and increased the risk of the NPC (OR=1.3, 95% CI=1.01-1.69). Also, we found that the frequency of the rs4986790 AA and rs4986791 TT genotypes was significantly higher in controls than in patients (25.7% vs 37%; p=0.006, pc=0.02) and conferred a protector factor in NPC (OR= 0.59, 95% CI= 0.39-0.87). Further, based on the Kaplan-Meier survival curve we observed also the positive effect ofrs1927914 AA genotype on a prognostic of NPC (p=0.006; pc=0.01).
Conclusion: Our study demonstrated that impaired production of TLR4 seems to be a risk factor of NPC development but functional studies are needed to confirm these findings. As to rs1927914 AA appears to be a good biomarker for better survival in a patient with NPC.
Downloads
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin 2018; 68: 394–424.
Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer 2018. https://gco.iarc.fr/today (accessed Dec 28, 2018).
Ben Ayoub Hizem W, Boussen H, Hsairi H, Ben Abdallah M. Nasopharyngeal Carcinoma Incidence in North Tunisia: Negative Trends in Adults but not Adolescents, 1994-2006.Asian Pac J Cancer Prev2015;16 (7), 2653-2657.
Chen YP, T C Chan A, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet 2019; 394: 64–80.
Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet 2016; 387: 1012–24.
Bei JX, Zuo XY, Liu WS, Guo YM, Zeng YX. Genetic susceptibility to the endemic form of NPC. Chin Clin Oncol 2016; 5: 15.
Wang HY, Chang YL, To KF, et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chin J Cancer 2016; 35: 41.
Chang Song, Li-Zhen Chen, Ru-Hua Zhang, Xing-Juan Yu, Yi-Xin Zeng. A functional variant in the 3'-untranslated region of tool-like receptor4 is associated with nasopharyngeal carcinoma risk. Cancer biology and therapy 2006; 5:10,1285-1291.
Becker, C.E. and L.A. O’Neill. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. In Seminars in immunopathology 2007. Springer.
Lafferty, E.I., S.T. Qureshi, and M. Schnare. The role of toll-like receptors in acute and chronic lung inflammation. J Inflamm (Lond) 2010;7:57.
Oberholzer, A., C. Oberholzer, and L.L. Moldawer. Sepsis syndromes: understanding the role of innate and acquired immunity.Shock2001;16(2): 83–96.
Hayashi, F, Smith K D, Ozinsky A, HawnT R, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410(6832):1099–1103.
Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Frontiers in Immunology 2014. 5: 316.
Ciesielska A, Matyjek M, Kwiatkowska K.TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cellular and Molecular Life Sciences 2021. 78 (4): 1233–1261.
El-Omar EM, Ng and GL HoldMT. Polymorphisms in Toll-like receptor genes and risk of cancer. 2008; Oncogen : 27, 244–252
FerwerdaB, McCallMB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med (Cambridge, Mass). 2008;14(5–6):346–52.
Arnott, I. D., E. R. Nimmo, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? . Genes Immun 2004; 5(5): 417-25.
Franchimont, D., S. Vermeire, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53(7): 987-92.
Oostenbrug, L. E., J. P. Drenth, et al. Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis 2005;11(6): 567-75.
Shen X, Shi R, Zhang H, Li K, Zhao Y, Zhang R. The Toll-like receptor 4 D299G and T399I polymorphisms are associated with Crohn's disease and ulcerative colitis: a meta-analysis. Digestion 81 2010;(2): 69-77.
He W, Liu Q, Wang L, Chen, Nan Li, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Molecular Immunology 2007; 44(11): 2850–2859.
Wang E, Qian Z R, Nakasono M, Tanahashi T, Yoshimoto K, Bando Yet al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poorprognosis in colorectal cancer. British Journal of Cancer 2010; 102(5): 908–915.
Szajnik, M, Szczepanski M J, Czystowska M, Elishaev E, Mandapathil M, Nowak-MarkwitzEet al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009; 28(49): 4353–4363.
Yang ZH, Dai Q, Gu YJ, Guo QX, Gong L. Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma. Cancer Sci; April 2012: 103(4) :653–658
Kutikhin A G. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Human Immunology 2011;72(2): 193–206.
Achyut, B, Ghoshal U, Moorchung N, Mittal B. Association of Toll-like receptor–4(Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Human Immunology 2007;68(11): 901–907.
RigoliL, Bella CD, Fedele F, Procopio V, Amorini M, Giudice G L et al. TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. AnticancerResearch2010; 30(2): 513–517.
Srivastava K, Anvesha S, Kumar A, Mittal Bet al. Significant association between toll‐like receptor gene polymorphisms and gallbladder cancer. Liver International 2010; 30(7): 1067–1072.
Kutikhin A G. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Human Immunology 2011: 72(2): 193–206.
Chen Y C, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter D J. Sequence variants of Toll-like receptor 4 andsusceptibility to prostate cancer. Cancer Research 2005 65(24): 11771–11778.
Tsilidis K K, Helzlsouer K J, Smith M W, Grinberg V, Hoffman-Bolton J, Clipp S L, Visvanathan K, Platz E P.Association of common polymorphismsin IL10, and in other genes related to inflammatory response andobesity with colorectal cancer. Cancer Causes and Control 2009 20(9):1739–1751.
Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis (2005) 5: 156–164.
Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Putter C, Wild CA, Schuler PJ, Greve J, Hoffmann TK, Lang S, Scherag A, Lehnerdt GF. 2011. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 2011 9:139.
Tina Bagratuni, Evangelos Terpos, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Maria Gavriatopoulou, Magdalini Migkou, et al TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. British Journal of Haematology, 2016; 172, 44–47.
Sumeet Jain, Sujit Suklabaidya, Biswajit Das, Sunil K. Raghav, et al. TLR4 Activation by Lipopolysaccharide Confers Survival Advantage to Growth Factor Deprived Prostate cancer cells. Prostate, 2015;1-11.
FerwerdaB, McCallMB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med (Cambridge, Mass). 2008;14(5–6):346–52.
Additional Files
Published
License
Copyright (c) 2024 La Tunisie Médicale
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
